UB Paderborn / Katalog / Suche / in CDI

Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412

Journal of clinical oncology, 2021-04, Vol.39 (12), p.1329-1338

2021

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Update of US GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil/Mitomycin Versus Fluorouracil/Cisplatin

Journal of clinical oncology, 2012-12, Vol.30 (35), p.4344-4351

2012

Link zum Volltext

Verfügbarkeit prüfen

Charting the Future of Cancer Health Disparities Research: A Position Statement From the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute

Journal of clinical oncology, 2017-09, Vol.35 (26), p.3075-3082

2017

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients With Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy

Journal of clinical oncology, 2011-01, Vol.29 (3), p.287-293

2011

Link zum Volltext

Verfügbarkeit prüfen

Impact of Overall Treatment Time on Survival and Local Control in Patients With Anal Cancer: A Pooled Data Analysis of Radiation Therapy Oncology Group Trials 87-04 and 98-11

Journal of clinical oncology, 2010-12, Vol.28 (34), p.5061-5066

2010

Link zum Volltext

Verfügbarkeit prüfen

Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma

Journal of clinical oncology, 2005-08, Vol.23 (22), p.5044-5051

2005

Link zum Volltext

Verfügbarkeit prüfen

Abbreviated Chemotherapy With Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab for Untreated Follicular Lymphoma

Journal of clinical oncology, 2005-08, Vol.23 (24), p.5696-5704

2005

Link zum Volltext

Verfügbarkeit prüfen

Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group

Journal of clinical oncology, 2019-04, Vol.37 (10), p.780-789

2019

Link zum Volltext

Verfügbarkeit prüfen

How a Child With Cancer Moved From Vulnerability to Resilience

Journal of clinical oncology, 2017-09, Vol.35 (27), p.3169-3171

2017

Link zum Volltext

Verfügbarkeit prüfen

Multivitamin Use Is Not Associated With Cancer Recurrence or Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803

Journal of clinical oncology, 2010-10, Vol.28 (28), p.4354-4363

2010

Link zum Volltext

Verfügbarkeit prüfen

Phase 1a/1b study design of the novel STING agonist, immune-stimulating antibody-conjugate (ISAC) TAK-500, with or without pembrolizumab in patients with advanced solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS2690-TPS2690

2022

Link zum Volltext

Verfügbarkeit prüfen

Alliance A059102: A randomized phase II U.S. intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS7593-TPS7593

2022

Link zum Volltext

Verfügbarkeit prüfen

Updated interim analysis of the randomized phase 1b/3 study of tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.7572-7572

2022

Link zum Volltext

Verfügbarkeit prüfen

PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)

Journal of clinical oncology, 2024-04, Vol.42 (10), p.1114-1123

2024

Link zum Volltext

Verfügbarkeit prüfen

A haploid genetic screen identifies the key determinant of response to novel combination therapy with gemcitabine and entinostat in pancreatic cancer

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e15685-e15685

2016

Link zum Volltext

Verfügbarkeit prüfen

Recurrence rates of resected appendix carcinoid tumors: A 20-year experience at Memorial Sloan Kettering Cancer Center

Journal of clinical oncology, 2016-02, Vol.34 (4_suppl), p.221-221

2016

Link zum Volltext

Verfügbarkeit prüfen

Patterns of care of locoregional radiation therapy in patients with stage IV rectal cancer: A SEER analysis

Journal of clinical oncology, 2013-02, Vol.31 (4_suppl), p.477-477

2013

Link zum Volltext

Verfügbarkeit prüfen

Measuring alignment with evidence-informed practice in Ontario’s systemic treatment funding model

Journal of clinical oncology, 2014-10, Vol.32 (30_suppl), p.15-15

2014

Link zum Volltext

Verfügbarkeit prüfen

A phase I, open-label study of GSK2816126, an enhancer of zeste homolog 2 (EZH2) inhibitor, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (tFL), other non-Hodgkin’s lymphomas (NHL), multiple myeloma (MM) and solid tumor

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS2595-TPS2595

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 trial results of DN24-02, a HER2-targeted autologous cellular immunotherapy in HER2+ urothelial cancer patients (pts)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.4513-4513

2016

Link zum Volltext

Verfügbarkeit prüfen

A secondary analysis of PSA response in NRG Oncology/RTOG 9902: A phase III trial of adjuvant chemotherapy with androgen suppression and radiation for high-risk prostate cancer (CaP)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.5078-5078

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II study of adoptive T-cell therapy following in vivo priming with a HER2/neu vaccine in patients with advanced-stage HER2 + breast cancer

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.615-615

2014

Link zum Volltext

Verfügbarkeit prüfen

Clinical utility of the 12-gene DCIS score assay: Impact on treatment (Tx) recommendations

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.11050-11050

2014

Link zum Volltext

Verfügbarkeit prüfen

Retrospective review of doxorubicin plus sorafenib as second-line therapy in hepatocellular carcinoma (HCC)

Journal of clinical oncology, 2012-02, Vol.30 (4_suppl), p.298-298

2012

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412

Long-Term Update of US GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil/Mitomycin Versus Fluorouracil/Cisplatin

Charting the Future of Cancer Health Disparities Research: A Position Statement From the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute

Randomized Phase II Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients With Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy

Impact of Overall Treatment Time on Survival and Local Control in Patients With Anal Cancer: A Pooled Data Analysis of Radiation Therapy Oncology Group Trials 87-04 and 98-11

Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma

Abbreviated Chemotherapy With Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab for Untreated Follicular Lymphoma

Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group

How a Child With Cancer Moved From Vulnerability to Resilience

Multivitamin Use Is Not Associated With Cancer Recurrence or Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803

Phase 1a/1b study design of the novel STING agonist, immune-stimulating antibody-conjugate (ISAC) TAK-500, with or without pembrolizumab in patients with advanced solid tumors

Alliance A059102: A randomized phase II U.S. intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas

Updated interim analysis of the randomized phase 1b/3 study of tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma

PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)

A haploid genetic screen identifies the key determinant of response to novel combination therapy with gemcitabine and entinostat in pancreatic cancer

Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2–) operable breast cancer (BC)

Recurrence rates of resected appendix carcinoid tumors: A 20-year experience at Memorial Sloan Kettering Cancer Center

Patterns of care of locoregional radiation therapy in patients with stage IV rectal cancer: A SEER analysis

Measuring alignment with evidence-informed practice in Ontario’s systemic treatment funding model

A phase I, open-label study of GSK2816126, an enhancer of zeste homolog 2 (EZH2) inhibitor, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (tFL), other non-Hodgkin’s lymphomas (NHL), multiple myeloma (MM) and solid tumor

Phase 2 trial results of DN24-02, a HER2-targeted autologous cellular immunotherapy in HER2+ urothelial cancer patients (pts)

A secondary analysis of PSA response in NRG Oncology/RTOG 9902: A phase III trial of adjuvant chemotherapy with androgen suppression and radiation for high-risk prostate cancer (CaP)

Phase I/II study of adoptive T-cell therapy following in vivo priming with a HER2/neu vaccine in patients with advanced-stage HER2 + breast cancer

Clinical utility of the 12-gene DCIS score assay: Impact on treatment (Tx) recommendations

Retrospective review of doxorubicin plus sorafenib as second-line therapy in hepatocellular carcinoma (HCC)

Aktive Filter

Suchergebnisse filtern